WebCilostazol is a medicine that can relieve claudication. Claudication is a common symptom of peripheral arterial disease (PAD). It causes pain in your legs when you walk or exercise. This happens because of reduced blood flow to your leg muscles. How cilostazol works. Cilostazol works by improving blood flow in the smallest blood vessels. WebApr 1, 2024 · Cilostazol improves the flow of blood through the blood vessels. It is used to reduce leg pain caused by poor circulation (intermittent claudication). Cilostazol makes it possible to walk farther before having to rest because of leg pain. This medicine works by keeping blood from clotting and by dilating or relaxing the blood vessels.
Cilostazol Erectile Dysfunction - IDEPEM Instituto De La …
WebAdult. 100 mg twice daily, to be taken 30 minutes before food, cilostazol should be initiated by those experienced in the management of intermittent claudication, patients receiving cilostazol should be assessed for improvement after 3 months; consider discontinuation … WebAbstract. Background: Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting.Methods: We performed a meta-analysis of all relevant randomized controlled trials (RCTs) to investigate the effect of TAT versus dual antiplatelet therapy (DAT) in terms of major … thai by jay
Cilostazol - StatPearls - NCBI Bookshelf
WebSep 10, 2024 · Cilostazol is a quinolinone derivative used for treatment of intermittent claudication and peripheral vascular disease. Learn about side effects, drug interactions, dosages, warnings, and more. Drugs & Vitamins Drugs A-Z Generic Drugs A-Z Drugs by … Webneck stiffness. a skin rash. coughing up of blood. chest pain. high amount of uric acid in the blood. high blood sugar. abnormal liver function tests. a significant type of allergic reaction ... WebJun 19, 2024 · Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving moderate inhibitors of CYP2C19. Monitor clinical response to cilostazol closely. Consider therapy modification. CYP2C19 Inhibitors (Strong): May increase serum concentrations of the active metabolite (s) of Cilostazol. symposium invitation letter